Drug Profile
Research programme: neuromuscular disorder therapeutics - Neurotune
Alternative Names: NT-1654Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Neurotune
- Class Biological factors; Small molecules
- Mechanism of Action Acetylcholine stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Congenital myasthenic syndromes; Myasthenia gravis; Peripheral nerve injuries; Sarcopenia; Spinal muscular atrophy
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in Congenital-myasthenic-syndromes in Switzerland (SC)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Myasthenia-gravis in Switzerland (SC)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Peripheral-nerve-injuries in Switzerland (SC)